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Abstract
Purpose of Review Molecular imaging with positron emission tomography (PET) is a powerful tool to visualize breast cancer
characteristics. Nonetheless, implementation of PET imaging into cancer care is challenging, and essential steps have been
outlined in the international “imaging biomarker roadmap.” In this review, we identify hurdles and provide recommendations
for implementation of PET biomarkers in breast cancer care, focusing on the PET tracers 2-[18F]-fluoro-2-deoxyglucose ([18F]-
FDG), sodium [18F]-fluoride ([18F]-NaF), 16α-[18F]-fluoroestradiol ([18F]-FES), and [89Zr]-trastuzumab.
Recent Findings Technical validity of [18F]-FDG, [18F]-NaF, and [18F]-FES is established and supported by international
guidelines. However, support for clinical validity and utility is still pending for these PET tracers in breast cancer, due to variable
endpoints and procedures in clinical studies.
Summary Assessment of clinical validity and utility is essential towards implementation; however, these steps are still lacking for
PET biomarkers in breast cancer. This could be solved by adding PET biomarkers to randomized trials, development of imaging
data warehouses, and harmonization of endpoints and procedures.
Keywords Breast cancer . Molecular imaging . Positron emission tomography . Technical validation . Clinical validation .
Clinical utility
Introduction
Over the last decade, there has been an increasing interest in
molecular imaging with positron emission tomography (PET),
in particular in the field of oncology. PET imaging is a non-
invasive tool to obtain qualitative and quantitative whole-
body information of biological processes. Molecular imaging
in breast cancer (BC) is of particular interest, as it can visualize
the estrogen receptor (ER), human epidermal growth factor
receptor 2 (HER2), and proliferation. However, molecular im-
aging with PET has not been widely adopted in clinical prac-
tice of BC. Only two radiotracers (2-[18F]-fluoro-2-
deoxyglucose ([18F]-FDG) and sodium [18F]-fluoride ([18F]-
NaF)) are incorporated in cancer management guidelines,
such as National Comprehensive Cancer Network (NCCN)
and European Society for Medical Oncology (ESMO). In or-
der to improve successful implementation of PET imaging
biomarkers into clinical practice, it is essential to identify po-
tential hurdles. Recently, an international consensus meeting
resulted in the “imaging biomarker roadmap,” describing the
steps of imaging biomarkers towards clinical practice [1••]. In
this review, we describe the current status of PET biomarkers
for BC, according to this roadmap. We identify specific chal-
lenges for each tracer individually and make recommenda-
tions for next steps towards clinical implementation.
Development Stages of Imaging Biomarkers
The imaging biomarker roadmap describes three parallel
tracks, towards biomarker implementation in clinical practice
[1••]. Technical validity, i.e., whether the test can be trusted,
requires harmonization and standardization of techniques as
an assessment of repeatability and reproducibility. Clinical
validity, i.e., whether the test is clinically meaningful, ad-
dresses the discriminatory value to predict diagnosis,
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prognosis, or therapy response. Finally, clinical utility, i.e.,
whether the test improves patient outcome and is cost-effec-
tive, is determined by health-related measurements.
Successful progress through these tracks is essential for a test
to pass from analytical to clinical research stage, and subse-
quently to routine clinical practice [1••].
Search Strategy
For this literature review, the database PubMed was searched
until September 2019. PET tracers were included if Food and
Drug Administration (FDA) approved or at least two prospec-
tive clinical articles, including ≥ 50 BC patients, were pub-
lished within the past 5 years. As a result, four radiotracers
were selected ([18F]-FDG, [18F]-NaF, 16α-[18F]-
fluoroestradiol ([18F]-FES), and zirconium-89 [89Zr]-
trastuzumab). Search terms were repeatability, reproducibili-
ty, inter- and intra-observer, diagnosis, prognosis, response to
treatment, survival, metastases, technical and clinical validity/
utility, cost-effectiveness, BC, PET, and meta-analysis.
Development Stages of [18F]-FDG-PET/CT
Technical Validity
[18F]-FDG-PET/computed tomography (CT) can detect in-
creased glucose metabolism in cancer cells and is indicated
for multiple oncological indications [2, 3]. [18F]-FDG is phos-
phorylated by the enzyme hexokinase and trapped inside
(tumor) cells [4]. The reproducibility and repeatability of
[18F]-FDG-PET/CT were assessed for various cancer types
(see Table 1 for overview) [58]. One meta-analysis of 5 stud-
ies, including 102 cancer patients of which 6 had metastatic
BC (MBC), assessed the repeatability of [18F]-FDG-PET(/
CT) by measuring the standardized uptake value (SUV)max/
mean in the same patient on two separate occasions with an
interval of 1–4 days [5]. A high test-retest interclass correla-
tion coefficient (ICC) of 0.90 and 0.91 was found for SUVmax
and SUVmean, respectively. Reproducibility across different
scanners was assessed in 23 patients, 17 with BC [13].
Patients underwent two [18F]-FDG-PET/CT scans within
15 days on the same scanner or on different scanners at dif-
ferent sites. Cross-calibration of PET/CT scanners and dose
calibrator was performed. The average difference in SUVmax
between test-retest [18F]-FDG-PET/CT, using the same scan-
ner, was 8% versus 18% on different scanners. International
standardization efforts to improve reproducibility resulted in
the European Association of Nuclear Medicine (EANM)
guideline for 18F imaging procedures, followed in 2010 by
the Research Ltd. (EARL) accreditation program to assure
independent quali ty control, comparable scanner
performance, and reproducible assessments [3, 59]. Since
2010, the number of accredited centers has increased over
time in Europe and beyond [60].
Clinical Validity
For [18F]-FDG-PET/CT, we focused on clinical validity stud-
ies with at least 100 BC patients. Ameta-analysis of 13 studies
(see Table 1) reported incidental and unexpected breast uptake
detected by [18F]-FDG-PET(/CT) [23]. Overlap between
SUVs in malignant and benign breast incidentalomas was
found, and not all lesions were further histologically exam-
ined. Therefore, [18F]-FDG-PET/CT is not routinely used for
diagnosis of primary BC. With regard to diagnosis of axillary
lymph node metastases in BC, a meta-analysis was performed
of studies comparing [18F]-FDG-PET(/CT) to the reference
standard: axillary lymph node dissection (ALND) or sentinel
lymph node biopsy (SLNB) [25]. In 7 out of 26 studies in-
volving 862 BC patients, [18F]-FDG-PET/CT sensitivity was
56% and specificity 96%, compared to 52% and 95% for
ALND and/or SLNB [25]. Another meta-analysis (21 studies
including 1887 BC patients), using ALND and/or SLNB as
reference standard, showed a sensitivity and specificity of
64% and 93%, respectively, for detection of axillary lymph
node metastases by [18F]-FDG-PET/CT [26•]. Based on these
data, [18F]-FDG-PET/CT is not recommended in the EANM,
NCCN, or ESMO guidelines for detection of axillary lymph
node metastases. However, as axillary BC management has
evolved over the last decades, the use of [18F]-FDG-PET/CT
in this setting may change as well. For instance, according to
the Dutch BC guideline, [18F]-FDG-PET/CT can be consid-
ered for staging of BC patients prior to neoadjuvant chemo-
therapy, although a biopsy of axillary lymph nodes with high
[18F]-FDG uptake is advised to avoid false positive results
[61]. With regard to [18F]-FDG-PET/CT for diagnosis of re-
current or distant metastases in BC, two meta-analyses includ-
ing a total of 2500 patients (2 studies with overlapping sub-
jects) showed both high sensitivity (92–96%) and specificity
(82–95%) [28, 29]. For the detection of bone metastases,
[18F]-FDG-PET/CT showed a sensitivity and specificity of
93% and 99%, versus 81% and 96% respectively, for conven-
tional bone scintigraphy, as determined in a meta-analysis
involving 668 BC patients in 7 studies [30]. According to
the EANM, ESMO, and NCCN guidelines, [18F]-FDG-PET/
CT should be considered in cases of suspected recurrence or
equivocal findings on standard imaging and can be used for
staging in high-risk BC patients [2, 3, 62, 63••, 64, 65••].
Despite the non-specific uptake of [18F]-FDG, preoperative
[18F]-FDG uptake, expressed as SUVmax, was found to be
related to prognostic pathological characteristics assessed on
core biopsy in primary BC. SUVmax was higher in ER− than
ER+ tumors (7.6 versus 5.5); higher uptake was also observed
in triple-negative tumors, tumor grade 3, ductal carcinoma,
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and p53 mutated tumors [31]. A meta-analysis of 15 studies
with 3574 BC patients evaluated the prognostic value of [18F]-
FDG uptake in primary breast lesions [32•]. High SUVmax
was related to a higher risk of recurrence or progression com-
pared with a low SUVmax. However, the SUVmax cutoff
values varied widely between studies, ranging from 3.0 to
11.1 [32•]. Lower baseline SUVmax predicted more favorable
survival outcomes than higher SUVmax (analyzed as a contin-
uous variable) [34]. The lack of clear cutoff values has so far
precluded the use of [18F]-FDG-PET as a prognostic tool in
BC. This is partly due to the fact that SUV calculations can
depend on the PET camera systems used. To harmonize the
acquisition protocols and the quantification process between
different camera systems, the EARL harmonization program
was introduced.
Clinical validity of serial [18F]-FDG-PET/CT to monitor
therapy response to neoadjuvant treatment was analyzed in
two meta-analyses (see Table 1), showing a pooled sensitivity
of 82–86% and specificity of 72–79%, using histopathology
as reference standard for pathological (non-)response [35,
36•]. Possibly differences between the pace of disease re-
sponse between BC subtypes may play a role in this setting.
In the randomized neoadjuvant study AVATAXHER in 142
patients with HER2+ BC, [18F]-FDG-PET/CT at baseline and
after 1 cycle of docetaxel/trastuzumab was used for further
treatment decisions [37]. Patients with a ΔSUVmax of ≥ 70%
(n = 69) continued docetaxel/trastuzumab. Patients with a
ΔSUVmax of < 70% (n = 73) were randomized for continued
docetaxel/trastuzumab or addition of bevacizumab. In all pa-
tients receiving docetaxel/trastuzumab, this ΔSUVmax cutoff
of 70% showed a positive and negative predictive value of
53% and 75%, respectively, to detect pathological complete
response. Recently, preliminary data from the neoadjuvant
PREDIX HER2 trial showed that pathological response was
related to decreased uptake on early [18F]-FDG-PET/CT com-
pared to baseline, in HER2+ primary BC [66]. For MBC, no
well-designed large study to assess the clinical value of [18F]-
FDG-PET/CT has been performed, only small studies with
varying endpoints [67, 68]. The optimal cutoff value and in-
terval between [18F]-FDG-PET/CT scans for response mea-
surement in BC are still unknown and may limit implementa-
tion of [18F]-FDG-PET/CT as a tool for early response predic-
tion in clinical practice. Attempts to integrate [18F]-FDG-PET/
CT in the Response Evaluation Criteria in Solid Tumors
(RECIST) criteria have not been successful so far, and [18F]-
FDG-PET/CT is not routinely used for response evaluation in
BC, due to the absence of sufficient clinical validation data
[69••, 70].
Clinical Utility
Evidence on the cost-effectiveness of [18F]-FDG-PET/CT in
BC is limited (Table 1). A Dutch computer simulation study
by Koleva-Kolarova et al. evaluated the effect of [18F]-FDG-
PET/CT on the number of performed biopsies and additional
costs compared to the standard clinical workup for diagnosing
ER+ MBC patients, using the incremental cost-effectiveness
ratio (ICER) to avoid a biopsy [55]. This study demonstrated a
38 ± 15% increase in biopsies, and higher costs for [18F]-
FDG-PET/CT compared to standard workup.
Conclusions and Recommendations of [18F]
-FDG-PET/CT
While the technical validity track for [18F]-FDG-PET/CT has
been completed successfully with international EARL and
EANM standardization and harmonization of the technique
itself, this harmonization is still lacking regarding clinical va-
lidity and utility. This has hampered routine use of [18F]-FDG-
PET/CT in BC management worldwide. First, studies estab-
lishing a receiver operating characteristic (ROC) curve, sensi-
tivity, and specificity in well-defined large cohort trials are
needed, with biopsy as gold standard. The IMPACT breast
trial (NCT01957332), in which baseline [18F]-FDG-PET/CT
was performed in 200MBC patients of all subtypes, including
biopsy of a metastasis and conventional imaging, is likely to
provide these data in the near future. Second, factors affecting
[18F]-FDG-PET/CT results other than treatment effects should
be standardized as much as possible (such as time of the scan
after therapy). Finally, clinical utility assessment by integrat-
ing imaging biomarkers into randomized trials, developing an
imaging data warehouse for EARL [18F]-FDG-PET/CT scans,
and performing meta-analyses of these data may provide the
final support for full implementation of [18F]-FDG-PET/CT
into clinical practice (Fig. 1).
Development Stages of [18F]-NaF-PET/CT
Technical Validity
Bone is the most common site of metastasis in BC. Two
PET tracers ([18F]-FDG and [18F]-NaF) are included in
EANM and NCCN guidelines to identify bone metastases
in BC patients. [18F]-NaF, approved by the FDA in 1972,
reflects enhanced bone metabolism due to bone metasta-
ses but also due to degeneration, arthritis, or fractures [71,
72]. The repeatability of [18F]-NaF-PET/CT was evaluat-
ed in a prospective multicenter study by Lin et al. in 35
prostate cancer patients with bone metastases who
underwent two pretreatment [18F]-NaF-PET/CT scans
(test-retest interval 3 ± 2 days), with SUVmean as most
repea tab le endpoin t (overv iew: Tab le 1) [18] .
Repeatability of SUVmean/max, functional tumor volume
(FTV50%), and total lesion [
18F]-fluoride uptake (TLF)
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measured with [18F]-NaF-PET/CT was confirmed by
Wassberg et al. [19]. Moreover, a high inter-observer
agreement at the patient level was found by using three
scales to define [18F]-NaF-PET/CT findings [21]. How to
correctly perform and interpret [18F]-NaF-PET/CT scans
is published in EANM and Society of Nuclear Medicine
and Molecular Imaging (SNMMI) guidelines, supporting
technical standardization and harmonization [73, 74].
Clinical Validity
At present, no comparison has been performed of [18F]-
NaF-PET/CT with a bone biopsy as the gold standard for
the entire study population, but it has been compared with
other imaging modalities. [18F]-NaF-PET/CT has a higher
sensitivity to detect bone metastases than either [18F]-
FDG-PET/CT or conventional bone scintigraphy with
99mTc-labeled diphosphonates (planar and SPECT) (97–
100% versus 74% versus 91%, respectively). However,
although the specificity of [18F]-NaF-PET/CT was higher
than that of bone scintigraphy, it was slightly lower than
[18F]-FDG-PET/CT (71–85% versus 63% and 97%, re-
spectively) [39, 40•]. In general, a negative [18F]-NaF-
PET/CT can be used to exclude bone metastases, but in
case of positive findings, [18F]-NaF-PET/CT should be
carefully interpreted and correlated with CT findings.
With regard to the prognostic value of [18F]-NaF-PET/
CT, one prospective study was performed in 28 BC pa-
tients with bone-dominant disease, showing no correlation
between baseline SUVmax and skeletal-related events,
time-to-progression or overall survival (OS) [41].
However, ΔSUVmax of 5 lesions between baseline and
~ 4 months of systemic treatment was associated with
OS [41]. With regard to the predictive value of [18F]-
NaF-PET/CT, two small studies showed that lack of en-
docrine treatment efficacy was related to an increase in
metabolic flux to mineral bone or SUVmax in BC patients
with bone only disease (see Table 1) [42, 44]. The nation-
al prospective oncologic PET registry of the USA showed
that [18F]-NaF-PET/CT altered the treatment plan in 39%
of BC patients [75]. However, the impact of [18F]-NaF-
PET/CT for therapy response on clinical decision-making
remains unclear due to varying endpoints and experimen-
tal procedures.
Clinical Utility
The cost-effectiveness of [18F]-NaF-PET(/CT) to detect bone
metastases was assessed in a meta-analysis of 11 trials, includ-
ing 425 patients (7 BC patients) [76]. It was concluded that the
average cost-effective ratio was less favorable for [18F]-NaF-
PET(/CT) than for conventional bone scintigraphy.
Conclusions and Recommendations of [18F]
-NaF-PET/CT
While the technical validation of [18F]-NaF-PET/CT is com-
pleted, clinical validation with comparison to a biopsy as ref-
erence standard is still warranted. Also, clinical validity of
[18F]-NaF-PET/CT should be further assessed with uniform
endpoints. Therefore, [18F]-NaF-PET/CT has not yet passed
through the necessary steps towards routine clinical practice
according to the imaging biomarker roadmap. Although in
bone-trope cancers such as BC, an optimal tool for diagnosis
and treatment evaluation is still needed and it is unclear
whether this tool could be [18F]-NaF-PET/CT.
Development Stages of [18F]-FES-PET/CT
Technical Validity
[18F]-FES-PET/CT enables the visualization of ER expres-
sion, with [18F]-FES behaving very similar to estradiol [77].
A large prospective cohort study of 90 BC patients with first
recurrence/metastatic disease and preliminary results from a
prospective study in 10 ER+ MBC patients showed an excel-
lent inter-observer agreement for [18F]-FES uptake (0.90 and
0.98, respectively) [22••, 78]. Although limited data about
repeatability and reproducibility are available, a recent guide-
line paper does provide recommendations regarding standard-
ization of scanning time, control of pre-analytical factors that
influence [18F]-FES uptake (such as discontinuation of estro-
gen receptor degraders > 5 weeks prior to scanning), visual
analysis, and quantification of [18F]-FES uptake [77].
Clinical Validity
A meta-analysis of 9 studies (all prospective, except one)
involving 238 patients reported a pooled sensitivity of 82%
and specificity of 95% to detect ER+ tumor lesions by
quantitative assessment of [18F]-FES uptake (overview:
Table 1) [45]. A similar sensitivity and specificity was
found in direct comparison of [18F]-FES uptake and ER
expression on biopsy (in 5 studies including 158 BC pa-
tients) [45]. Recently, a large prospective cohort study was
published involving 90 BC patients with first recurrence/
metastatic disease, comparing the correlation between
qualitative [18F]-FES-PET/CT results and immunohisto-
chemistry (IHC) of ER status of the same metastatic lesion.
This resulted in a positive and negative predictive value of
100% and 78%, respectively [22••]. A quantitative analysis
was also performed, showing a positive and negative
agreement of [18F]-FES-PET/CT (threshold SUVmax 1.5)
with ER IHC equaling 85% and 79%, respectively.
Despite the importance of this well-defined prospective
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Fig. 1 Upper image: three PET scans ([18F]-FDG-PET, [18F]-FES-PET,
and [89Zr]-trastuzumab-PET) in the same patient showing mediastinal
and hilar lymph node metastases, as well as intrapulmonary lesions
visible on both [18F]-FDG-PET and [18F]-FES-PET, but not on [89Zr]-
trastuzumab-PET. The large mediastinal mass (first row of transversal
fused images) was visible on all three imaging modalities. Bone
metastases (second row of transversal fused images) were clearly
visualized on [18F]-FES-PET, for example, skull lesions, and to a lesser
extent on [18F]-FDG-PET and [89Zr]-trastuzumab-PET. Lower image:
[18F]-NaF-PET in another patient showing bone metastases in the skull,
vertebrae, costae, pelvis, and proximal femora. The increased uptake in
the joint was related to degeneration
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cohort trial, its impact is likely limited due to exclusion of
bone metastases, the most common metastatic site in ER+
MBC. Furthermore, an optimal SUVmax cutoff to distin-
guish benign from malignant lesions by [18F]-FES-PET/
CT has not been established. Although SUVmax 1.5 is most
commonly used for this distinction, ranges of 1.0 to 2.0
have also been described. Yang et al. determined an ROC
curve in 46 ER+ BC patients, showing an optimal SUVmax
cutoff of 1.8, with a sensitivity of 88% and specificity of
88% (optimal SUVmean cutoff: 1.2) [79]. The study of
Nienhuis et al. in 91 ER+ MBC patients found that phys-
iological background uptake could exceed SUVmax 1.5, for
example, in the lumbar spine [80]. [18F]-FES-PET/CT
scans performed in 108 individuals showed that irradiation
could induce atypical (non-malignant) enhanced [18F]-FES
uptake in the lungs [81]. These issues should be taken into
account in interpreting [18F]-FES-PET/CT scans for the
diagnosis of BC. However, these data are retrospective
and should be interpreted with caution. Nonetheless, two
trials have indicated usefulness of [18F]-FES-PET(/CT) for
the physician by improving diagnostic understanding com-
pared to conventional assessments in 88% of patients, and
causing a treatment change in 48–49% of patients enrolled
in the studies [82, 83]. Therefore, [18F]-FES-PET/CT may
be a useful diagnostic tool in exceptional diagnostic di-
lemmas when added to a conventional workup. A prospec-
tive study involving 90 ER+ BC patients treated with en-
docrine therapy found that [18F]-FES-PET(/CT) may be a
useful prognostic biomarker for [18F]-FDG avid tumors,
demonstrating a higher median progression-free survival
(PFS) in the high [18F]-FES uptake group compared to
low [18F]-FES uptake group (7.9 versus 3.3 months, re-
spectively) [48]. With regard to response prediction, a
meta-analysis including 6 prospective trials and 183 pa-
tients found a pooled sensitivity of 64% and specificity
of 29% to predict early or late response to hormonal ther-
apy, with an SUVmax cutoff of 1.5, and a sensitivity of 67%
and specificity of 62% with SUVmax of 2.0 [45]. In 26
patients with primary ER+ BC, randomized to neoadjuvant
chemotherapy or endocrine treatment, no differences in
baseline SUVmax were found between post-treatment path-
ological (non-) responders [49•]. In another small trial (in-
cluding 18 patients), pathological response to neoadjuvant
chemotherapy was related to low rather than high baseline
SUVmax (1.8 versus 4.4) [84]. Overall, it is difficult to
compare this data due to the heterogeneity of the trials,
i.e., different endpoints, and imaging procedures.
Clinical Utility
Two computer simulation studies described the impact of
[18F]-FES-PET/CT on health-related measurements, such as
life years gained (LYG), ICER, and total costs (Table 1) [55,
56]. One study selected first-line treatment in MBC patients
based on biopsy results or [18F]-FES-PET/CT imaging find-
ings and showed higher diagnostic and treatment costs in the
PET/CT imaging group [56]. A second study determined the
number of avoided biopsies to assess MBC after the introduc-
tion of [18F]-FES-PET/CT and showed that the number of
biopsies (39 ± 9%) was lower in the [18F]-FES-PET/CT imag-
ing group [55].
Conclusions and Recommendations of [18F]
-FES-PET/CT
While [18F]-FES-PET/CT is currently used in a limited num-
ber of hospitals worldwide, mostly in a research setting, but
also as a diagnostic tool in exceptional diagnostic dilemmas,
consistent data to support its clinical validity and utility are
still lacking. Only in France is [18F]-FES approved for routine
clinical use to determine ER status in MBC. In order to im-
plement [18F]-FES-PET/CT more broadly in routine clinical
practice, additional studies are needed. Within two prospec-
tive cohort trials, the multicenter IMPACT breast trial and the
ECOG-ACRIN trial (NCT02398773; 99 newly diagnosed
MBC patients), the analysis of baseline [18F]-FES uptake re-
lated to treatment response or PFS is ongoing. In the ongoing
ET-FES TRANSCAN trial (EUDRACT 2013-000-287-29),
the treatment choice is based on [18F]-FES-PET/CT (high ver-
sus low 18F-FES uptake) [85]. [18F]-FES-PET/CT is also
added as integrated biomarker to another randomized con-
trolled trial, the SONImage trial (NCT04125277). With these
additional studies, sufficient evidence could potentially be
generated to support implementation of [18F]-FES-PET/CT
in routine clinical practice.
Development Stages of [89Zr]
-Trastuzumab-PET/CT
Technical Validity
The [89Zr]-labeled antibody trastuzumab binds to the HER2-
receptor and has a relatively long half-life (t ½ = 78 h). This
enables imaging at late time points but also limits repeatability
testing as radiation dose is high and repeated scans would
require a 2-week interval [86]. To optimize the acquisition
protocol, imaging at multiple time points (after 1–7 days)
was performed after a single tracer injection [87, 88]. The
optimal time point was found after 4–5 days, due to lower
background uptake and higher contrast. Recently, a [89Zr]-
PET/CT EARL accreditation program was established, simi-
lar to [18F]-FDG-PET/CT accreditation [60, 89, 90••].
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Clinical Validity
No comparison of [89Zr]-trastuzumab-PET/CT with biopsy
has been performed so far. In a prospective study including
34 HER2+ and 16 HER2− BC patients, an SUVmax cutoff of
3.2 showed a sensitivity of 76% and specificity of 62% to
distinguish HER2+ from HER2− lesions [53]. The HER2 sta-
tus was based on the primary tumor or metastatic lesion; how-
ever, a recent biopsy of a tumor lesion was not performed in
all patients. Despite this relatively low discriminative value,
[89Zr]-trastuzumab-PET/CT did support diagnostic under-
standing and resulted in a treatment change in 90% and 40%
of patients respectively, in whom HER2 status could not be
determined by standard workup [91]. With regard to the prog-
nostic value of [89Zr]-trastuzumab-PET/CT no data are avail-
able, but its value to predict therapy response was assessed in
the ZEPHIR trial (see Table 1) [54]. In 56 HER2+ MBC
patients, qualitative analysis of baseline PET/CT scans indi-
cated that [89Zr]-trastuzumab uptake was related to longer
trastuzumab emtansine treatment duration, compared to no
uptake (11.2 versus 3.5 months) [54].
Clinical Utility
A computer simulated study of a hypothetical cohort of 1000
MBC patients assessed whether [89Zr]-trastuzumab-PET/CT
could replace biopsy [56]. This study concluded that total
costs were higher with [89Zr]-trastuzumab-PET/CT.
However, biopsy effects on quality of life were not included
in the analysis.
Conclusions and Recommendations of [89Zr]
-Trastuzumab-PET/CT
Although technical standardization and harmonization is sup-
ported by the recently introduced [89Zr]-PET/CT EARL ac-
creditation program, at present, still significant knowledge
gaps exist (for instance regarding the relation between biopsy
and uptake on [89Zr]-trastuzumab-PET/CT) [89]. Therefore,
multiple steps according to the imaging biomarker roadmap
have to be taken before [89Zr]-trastuzumab-PET/CT can be
implemented in clinical practice. It is expected that the previ-
ously mentioned multicenter IMPACT breast study will pro-
vide information that can advance the validation of [89Zr]-
trastuzumab-PET/CT.
Other PET Tracers for Molecular Imaging in BC
Multiple new tracers of potential interest in BC can be
identified (see Table 2). PET imaging of additional recep-
tors may be the next step, for example, the hormone
receptor tracer [18F]-dihydrotesterone ([18F]-FDHT)-PET,
which is commonly used in prostate cancer trials. This
tracer provides information about androgen receptor
(AR) expression, which is a potential new target for BC
treatment [46]. Moreover, cell proliferation can be detect-
ed by [18F]-fluorothymidine ([18F]-FLT)-PET, and post-
neoadjuvant chemotherapy [18F]-FLT uptake may be cor-
related with the proliferation marker Ki-67 measured by
IHC in primary BC patients [92]. In light of the current
developments in BC immunotherapy, assessment of the
programmed death-ligand 1 (PD-L1) with [89Zr]-labeled
atezolizumab is clearly of interest. Recently, a first-in-
human study with 22 patients (including 4 with triple-
negative BC) showed a better correlation of [89Zr]-
atezolizumab uptake to treatment response, PFS and OS
at patient level than the commonly used SP142 IHC mark-
er [93]. Currently, one recruiting [89Zr]-atezolizumab-PET
study is available for lobular BC (NCT04222426).
Furthermore, a combination of molecular imaging tech-
niques, such as [18F]-FES-PET, [89Zr]-trastuzumab-PET
with [18F]-FDG-PET, may be useful in identifying disease
heterogeneity or differentiating between indolent and ag-
gressive disease [48, 54, 94]. This could help to select the
best therapeutic strategy.
Conclusions
In this review, we identified hurdles based on the bio-
marker roadmap for the four most commonly used PET
tracers in BC and made recommendations for the next
steps towards clinical implementation. This review has
summarized several important steps to be considered to
successfully implement molecular biomarkers for BC pa-
tients in clinical practice. In general, support for clinical
utility is still pending for PET tracers in BC, but also
assessment of clinical validity is hampered by varying
endpoints and procedures. Improving trial designs can
contribute to solve this matter; for instance, multicenter
trials require standardization and harmonization of proce-
dures. International collaboration is essential, as this
would also potentially allow building warehouses of data
to overcome a plethora of small solitary single center
studies. Based on these warehouses, clinical validation
can be established in line with the RECIST guidelines.
In this setting, considering all aspects of the biomarker
roadmap at an early stage is important. Smart trial designs
adding imaging biomarkers to randomized controlled tri-
als (integrated biomarker) are desirable, as imaging
biomarker–based randomized controlled trials (integral
biomarker) are usually not feasible due to the large num-
bers of patients required [95]. From a regulatory point of
view, the evidence required for implementation is still
85    Page 10 of 16 Curr Oncol Rep (2020) 22: 85
Table 2 Ongoing PET imaging based clinical trials including breast cancer patients (n = 48)








[18F]-FES ER ER+, HER2− MBC 60 NA NCT03442504 2017 Recruiting
ER+, HER2− MBC 8 I/II NCT04150731 2020 Not yet recruiting
ER+ (M)BC 60 III NCT03544762 2017 Recruiting
ER+, HER2− MBC 75 II NCT02409316 2015 Recruiting
ER+ MBC 68 NA NCT03768479 2017 Recruiting





40 NA NCT03726931 2018 Recruiting
ER−, HER2+ MBC 33 NA NCT03619044 2019 Not yet recruiting
ER+ MBC 100 NA NCT04125277 2019 Recruiting
ER+ MBC 99 II NCT02398773 2016 Recruiting
ER+, HER2− MBC 25 NA NCT03873428 2020 Not yet recruiting
ER+ (M)BC 100 I NCT01916122 2013 Recruiting




217 NA NCT01957332 2013 Active, not
recruiting
ER+ (M)BC 29 NA NCT02149173 2010 Active, not
recruiting
ER+, HER2− MBC 16 I NCT02650817 2016 Active, not
recruiting
ER+ MBC 15 NA NCT01720602 2012 Active, not
recruiting
[18F]-FDHT AR AR+, HER2− MBC 22 II NCT02697032 2016 Active, not
recruiting
[18F]-FTT PARP-1 (M)BC 30 NA NCT03846167 2019 Recruiting
BC 30 I NCT03083288 2017 Active, not
recruiting
[18F]-ISO-1 Sigma-2 receptor MBC 30 NA NCT03057743 2016 Recruiting





status, Rb + MBC
20 I NCT02608216 2015 Recruiting
MBC 17 NA NCT01621906 2012 Active, not
recruiting
[18F]-FMISO Hypoxic cells ER−, HER2− MBC 126 II NCT02498613 2016 Recruiting
[18F]-GE-226 HER2 MBC 16 NA NCT03827317 2019 Recruiting
[18F]-F-GLN Glutamine
metabolism
(M)BC 30 NA NCT03863457 2019 Recruiting
[18F]-αvβ6-BP αvβ6 (M)BC 27 I NCT03164486 2016 Recruiting
[18F]-Var3 Extracellular pH MBC 10 I NCT04054986 2019 Recruiting




BC 120 NA NCT03144622 2016 Recruiting
[18F]-FAZA Hypoxic cells BC 25 I NCT03168737 2017 Recruiting
[18F]-ASIS Tissue factor (M)BC 10 I NCT03790423 2019 Recruiting
[89Zr]-Trastuzumab HER2 Regardless of ER/HER2
status, MBC
217 NA NCT01957332 2013 Active, not
recruiting
[89Zr]-Atezolizumab PD-L1 ER−, HER2− MBC 54 NA NCT02453984 2016 Recruiting
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unclear, although European Medicines Agency and FDA
acknowledge that a microdose radiopharmaceutical is not
similar to a therapeutic drug in this respect [96, 97].
Nonetheless, establishing whether patient outcome is truly
improved is essential to justify implementation of a com-
plex, expensive tool with radiolabeled PET tracers. A
considerable international, collaborative effort could po-
tentially make this possible.
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Table 2 (continued)








Lobular ER+ MBC 10 NA NCT04222426 2019 Recruiting
[89Zr]-CED88004S CD8 ER−, HER2− MBC 40 I/II NCT04029181 2019 Recruiting
[89Zr]-Bevacizumab VEGF Inflammatory HER2−
(M)BC
10 I NCT01894451 2015 Active, not
recruiting
[68Ga]-ABY-025 HER2 HER2+ (M)BC 120 NA NCT03655353 2018 Recruiting
[68Ga]-RM2 Gastrin-releasing
peptide receptor
ER+ BC 80 III NCT03731026 2018 Not yet recruiting
[68Ga]-NOTA-Anti-HER2
VHH1
HER2 MBC 20 II NCT03924466 2019 Recruiting
MBC 30 II NCT03331601 2017 Recruiting
[68Ga]-FAPI-46 Fibroblast
activated protein




(M)BC 30 I NCT04147494 2019 Not yet recruiting
[64Cu]-DOTA-Trastuzumab HER2 HER2+ BC 20 II NCT02827877 2016 Recruiting
HER2+ MBC 18 NA NCT01093612 2011 Active, not
recruiting





BC 6 I NCT03542695 2020 Not yet recruiting
[64Cu]-M5A Carcinoembryonic
antigen




Locally advanced BC 124 II NCT02086578 2014 Active, not
recruiting
Searched for breast cancer and positron emission tomography in ClinicalTrials.gov. Only trials which have not been published and had a recruitment
status of active, (not yet) recruiting were included. Combined PET/MRI scans and [18F]-FDG-PET scans were excluded
(M)BC (metastatic) breast cancer, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, AR androgen receptor, NA not applicable,
PARP poly ADP ribose polymerase, PD-L1 programmed death-ligand 1, VEGF vascular endothelial growth factor
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